Eucalyptus oil is the generic name for distilled oil from the leaf of Eucalyptus, a genus of the plant family Myrtaceae native to Australia and cultivated worldwide. Eucalyptus oil has a history of wide application, as a pharmaceutical, antiseptic, repellent, flavouring, fragrance and industrial uses. The leaves of selected Eucalyptus species are steam distilled to extract eucalyptus oil.
- Types and production 1
- Medicinal and antiseptic 2.1
- Repellent and biopesticide 2.2
- Flavouring 2.3
- Fragrance 2.4
- Industrial 2.5
- Safety and toxicity 3
- History 4
- Species utilised 5
- Compendial status 6
- See also 7
- References 8
- Further reading 9
- External links 10
Types and production
Eucalyptus oils in the trade are categorized into three broad types according to their composition and main end-use: medicinal, perfumery and industrial. The most prevalent is the standard cineole-based "oil of eucalyptus", a colourless mobile liquid (yellow with age) with a penetrating, camphoraceous, woody-sweet scent.
China produces about 75% of the world trade, but most of this is derived from camphor oil fractions rather than being true eucalyptus oil. Significant producers of true eucalyptus oil include South Africa, Portugal, Spain, Brazil, Australia, Chile and Swaziland.
Global production is dominated by Eucalyptus globulus. However, Eucalyptus kochii and Eucalyptus polybractea have the highest cineole content, ranging from 80-95%. The British Pharmacopoeia states that the oil must have a minimum cineole content of 70% if it is pharmaceutical grade. Rectification is used to bring lower grade oils up to the high cineole standard required. Global annual production of eucalyptus oil is estimated at 3,000 tonnes. The eucalyptus genus also produces non-cineole oils, including piperitone, phellandrene, citral, methyl cinnamate and geranyl acetate.
Medicinal and antiseptic
The cineole-based oil is used as component in pharmaceutical preparations to relieve the symptoms of influenza and colds, in products like cough sweets, lozenges, ointments and inhalants. Eucalyptus oil has antibacterial effects on pathogenic bacteria in the respiratory tract. Inhaled eucalyptus oil vapor is a decongestant and treatment for bronchitis. Cineole controls airway mucus hypersecretion and asthma via anti-inflammatory cytokine inhibition. Eucalyptus oil also stimulates immune system response by effects on the phagocytic ability of human monocyte derived macrophages.
Repellent and biopesticide
Eucalyptus oil is used in
- Toxicity Eucalyptus oil profile, Chemical Safety Information from Intergovernmental Organizations
- Eucalyptus oil (E. globulus Labillardiere, E. fructicetorum F. Von Mueller, E. smithii R.T. Baker) MedlinePlus, U.S. National Library of Medicine, U.S. National Institutes of Health evidence-based monograph prepared by the Natural Standard Research Collaboration
- Boland, D.J., Brophy, J.J., and A.P.N. House, Eucalyptus Leaf Oils, 1991, ISBN 0-909605-69-6
- FAO Corporate Document Repository, Flavours and fragrances of plant origin
- William M. Ciesla. "Types of oil and uses". Non-wood Forest Products from Temperate Broad-leaved Trees. Food & Agriculture Org (2002). p. 30.
- Lawless, J., The Illustrated Encyclopedia of Essential Oils, Element Books 1995 ISBN 1-85230-661-0
- Ashurst, P. R (1999-07-31). Food Flavorings.
- Salari, M. H.; Amine, G.; Shirazi, M. H.; Hafezi, R.; Mohammadypour, M. (2006). "Antibacterial effects of Eucalyptus globulus leaf extract on pathogenic bacteria isolated from specimens of patients with respiratory tract disorders". Clinical Microbiology and Infection 12 (2): 194–6.
- Lu, XQ; Tang, FD; Wang, Y; Zhao, T; Bian, RL (2004). "Effect of Eucalyptus globulus oil on lipopolysaccharide-induced chronic bronchitis and mucin hypersecretion in rats". Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 29 (2): 168–71.
- Juergens, U.R; Dethlefsen, U; Steinkamp, G; Gillissen, A; Repges, R; Vetter, H (2003). "Anti-inflammatory activity of 1.8-cineol (eucalyptol) in bronchial asthma: A double-blind placebo-controlled trial". Respiratory Medicine 97 (3): 250–6.
- Juergens, Uwe R.; Engelen, Tanja; Racké, Kurt; Stöber, Meinolf; Gillissen, Adrian; Vetter, Hans (2004). "Inhibitory activity of 1,8-cineol (eucalyptol) on cytokine production in cultured human lymphocytes and monocytes". Pulmonary Pharmacology & Therapeutics 17 (5): 281–7.
- Serafino, A; Sinibaldi Vallebona, PS; Andreola, F; Zonfrillo, M; Mercuri, L; Federici, M; Rasi, G; Garaci, E; Pierimarchi, P (2008). "Stimulatory effect of Eucalyptus essential oil on innate cell-mediated immune response". BMC Immunology 9: 17.
- Göbel, H; Schmidt, G; Soyka, D (1994). "Effect of peppermint and eucalyptus oil preparations on neurophysiological and experimental algesimetric headache parameters". Cephalalgia : an international journal of headache 14 (3): 228–34; discussion 182.
- Hong, CZ; Shellock, FG (1991). "Effects of a topically applied counterirritant (Eucalyptamint) on cutaneous blood flow and on skin and muscle temperatures. A placebo-controlled study". American journal of physical medicine & rehabilitation / Association of Academic Physiatrists 70 (1): 29–33.
- Nagata, Hideki; Inagaki, Yoshika; Tanaka, Muneo; Ojima, Miki; Kataoka, Kosuke; Kuboniwa, Masae; Nishida, Nobuko; Shimizu, Katsumasa; Osawa, Kenji; Shizukuishi, Satoshi (2008). "Effect of Eucalyptus Extract Chewing Gum on Periodontal Health: A Double-Masked, Randomized Trial". Journal of Periodontology 79 (8): 1378–85.
- Flower and Vegetable Oils, R.E.D. Facts, EPA
- Harborne, J.B., Baxter, H., Chemical Dictionary of Economic Plants, ISBN 0-471-49226-4
- Zhao, J., Agboola, S., Functional Properties of Australian Bushfoods - A Report for the Rural Industries Research and Development Corporation, 2007, RIRDC Publication No 07/030
- Boland, D.J., Brophy, J.J., and A.P.N. House, Eucalyptus Leaf Oils, 1991, p. 8 ISBN 0-909605-69-6
- Darben, T; Cominos, B; Lee, CT (1998). "Topical eucalyptus oil poisoning". The Australasian journal of dermatology 39 (4): 265–7.
- Hindle, R.C. (1994). "Eucalyptus oil ingestion". New Zealand Medical Journal: 185–186.
- Foggie, WE (1911). "Eucalyptus Oil Poisoning". British Medical Journal 1 (2616): 359–360.
- Low, T., Bush Medicine, A Pharmacopeia of Natural Remedies, Angus & Robertson, p. 85, 1990.
- Barr, A., Chapman, J., Smith, N., Beveridge, M., Traditional Bush Medicines, An Aboriginal Pharmacopoeia, Greenhouse Publications, pp. 116–117, 1988, ISBN 086436167X
- Maiden, J.H., The Forest Flora of New South Wales, vol. 4, Government Printer, Sydney, 1922.
- Copy of letter received by Dr Anthony Hamiltion, from Dennis Considen, 18 November 1788, and sent onto Joseph Banks.
- Lassak, E.V., & McCarthy, T., Australian Medicinal Plants, Methuen Australia, 1983, p. 15, ISBN 0-454-00438-9.
- , 1790Journal of a Voyage to New South WalesWhite, J.,
- Grieve, M.,(author) & Leyel, C.F., (ed), A Modern Herbal, Jonathon Cape, 1931, p. 287.
- Boland, D.J., Brophy, J.J., and A.P.N. House, Eucalyptus Leaf Oils, 1991, p. 6 ISBN 0-909605-69-6
- Maiden, J.H., The Useful Native Plants of Australia, pp. 255, 1889
- The British Pharmacopoeia Secretariat (2009). "Index, BP 2009" (PDF). Retrieved 10 September 2009.
- Essential oil
- Eucalypts, woody plants belonging to three closely related genera: Eucalyptus, Corymbia and Angophora
- Eucalyptus dives - phellandrene variant
- Eucalyptus dives - piperitone variant
- Eucalyptus elata - piperitone variant
- Eucalyptus macarthurii - geranyl acetate
- Eucalyptus olida - methyl cinnamate
- Eucalyptus radiata - phellandrene variant
- Eucalyptus staigeriana - citral, limonene
Non-cineole oil producing species:
- Eucalyptus cneorifolia
- Eucalyptus dives
- Eucalyptus dumosa
- Eucalyptus globulus
- Eucalyptus goniocalyx
- Eucalyptus horistes
- Eucalyptus kochii
- Eucalyptus leucoxylon
- Eucalyptus oleosa
- Eucalyptus polybractea
- Eucalyptus radiata
- Eucalyptus sideroxylon
- Eucalyptus smithii
- Eucalyptus tereticornis
- Eucalyptus viridis
Commercial cineole-based eucalyptus oils are produced from several species of Eucalyptus:
The Australian eucalyptus oil industry peaked in the 1940s, the main area of production being the central goldfields region of Victoria, particularly Inglewood; then the global establishment of eucalyptus plantations for timber resulted in increased volumes of eucalyptus oil as a plantation by-product. By the 1950s the cost of producing eucalyptus oil in Australia had increased so much that it could not compete against cheaper Spanish and Portuguese oils (closer to European Market therefore less costs). Non-Australian sources now dominate commercial eucalyptus oil supply, although Australia continues to produce high grade oils, mainly from blue mallee (E. polybractea) stands.
French chemist, F.S. Cloez, identified and ascribed the name eucalyptol — also known as cineole — to the dominant portion of E. globulus oil. By the 1870s oil from Eucalyptus globulus, Tasmanian blue gum, was being exported worldwide and eventually dominated world trade, while other higher quality species were also being distilled to a lesser extent. Surgeons were using eucalyptus oil as an antiseptic during surgery by the 1880s.
Baron Ferdinand von Mueller, Victorian botanist, promoted the qualities of Eucalyptus as a disinfectant in "fever districts", and also encouraged Joseph Bosisto, a Melbourne pharmacist, to investigate the commercial potential of the oil. Bosisto started the commercial eucalyptus oil industry in 1852 near Dandenong, Victoria, Australia, when he set up a distillation plant and extracted the essential oil from the cineole chemotype of Eucalyptus radiata. This resulted in the cineole chemotype becoming the generic 'oil of eucalyptus', and "Bosisto's Eucalyptus Oil" still survives as a brand.
Dennis Considen and John White, surgeons on the First Fleet, distilled eucalyptus oil from Eucalyptus piperita found growing on the shores of Port Jackson in 1788 to treat convicts and marines. Eucalyptus oil was subsequently extracted by early colonists, but was not commercially exploited for some time.
The probable lethal dose of pure eucalyptus oil for an adult is in the range of 0.05 mL to 0.5 mL/per kg of body weight. Because of their high body surface area to mass ratio, children are more vulnerable to poisons absorbed transdermally. Severe poisoning has occurred in children after ingestion of 4 mL to 5 mL of eucalyptus oil.
If consumed internally at low dosage as a flavouring component or in pharmaceutical products at the recommended rate, cineole-based 'oil of eucalyptus' is safe for adults. However, systemic toxicity can result from ingestion or topical application at higher than recommended doses.
Safety and toxicity
Research shows that cineole-based eucalyptus oil (5% of mixture) prevents the separation problem with ethanol and petrol fuel blends. Eucalyptus oil also has a respectable octane rating and can be used as a fuel in its own right. However, production costs are currently too high for the oil to be economically viable as a fuel.